Показано 0 из 0
Дата |
---|
17.05.2024 |
16.05.2024 |
15.05.2024 |
14.05.2024 |
13.05.2024 |
10.05.2024 |
09.05.2024 |
08.05.2024 |
07.05.2024 |
06.05.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.86
|
1.06
|
1.04
|
1.04
|
1.04
|
1.04
|
|
|
|
|
0.882
|
1.08
|
1.04
|
1.04
|
1.04
|
1.04
|
|
|
|
|
1.04
|
1.24
|
0.74
|
0.74
|
0.74
|
0.74
|
|
|
|
|
0.74
|
0.94
|
0.74
|
0.74
|
0.74
|
0.74
|
|
|
|
|
0.66
|
0.86
|
0.74
|
0.74
|
0.74
|
0.74
|
|
|
|
|
0.702
|
0.902
|
0.74
|
0.74
|
0.74
|
0.74
|
|
|
|
|
0.656
|
0.856
|
0.74
|
0.74
|
0.74
|
0.74
|
|
|
|
|
0.74
|
0.94
|
0.448
|
0.448
|
0.448
|
0.448
|
|
|
|
|
0.448
|
0.648
|
0.37
|
0.37
|
0.37
|
0.37
|
|
|
|
|
0.304
|
0.504
|
0.37
|
0.37
|
0.37
|
0.37
|
|
|
|
|
Acticor Biotech is specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II clinical development (Glenzocimab).